Company

Research programs

  • QGC001 for the treatment of high blood pressure with monotherapy drug, which is in clinical phase II
  • QGC011 for the treatment of high blood pressure with combination therapy, in pre-clinical phase
  • QGC006 to optimize the treatment of high blood pressure with a monotherapy drug
  • QGC101, for the prevention and treatment of heart failure, in pre-clinical phase

Quantum Genomics

Quantum Genomics is a biopharmaceutical company whose mission is to develop new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics’ research programs are based on the Brain Aminopeptidase A Inhibition (BAPAI), a real triple action innovative therapeutic platform, licensed from the academic research laboratories of the Collège de France, INSERM and CNRS.

Quantum Genomics is the only biopharmaceutical company developing new therapies acting through brain aminopeptidase A inhibition.